11.03.2013 - Genmab's antibody drug inclacumab significantly reduces damage to the heart muscle during angioplasty, Canadian researchers reported at the ACC Meeting.
In patients with acute coronary syndrome (ACS), who were treated by opening the blocked artery (Angioplasty/Percutaneous Coronary Intervention, PCI), Inclacumab (RO4905417, RG1512) helped significantly to lower the levels of a biomarker clinically used to diagnose heart attacks. A single shot of the human anti-inflammatory antibody, which is co-developed by Genmab and Roche, reduced Troponin I levels by 24%, said Principal Investigator Dr. Jean-Claude Tardif from University of Montreal at the international meeting of the American College of Cardiology (ACC) on 10 March.
"Inclacumab could indeed become an integral part of the therapeutic arsenal of modern cardiology if we can reproduce these results in subsequent studies", said the Director of the Research Centre at the Montreal Heart Institute. "We could use the drug for a broader patient population, or for all patients who present with a heart attack, but this will require further study." The human antibody targets P-selectin, a molecule which plays an important role in sending white blood cells to the site of an injury during inflammation.
The Phase II trial conducted by Roche involved 530 patients with myocardial infarction who were randomised to receive an infusion of inclacumab at 20 mg/kg, inclacumab at 5 mg/kg, or placebo 1 to 24 hours before angioplasty. Markers for heart damage were then measured at 8, 16 and 24 hours after angioplasty.
12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.